Conjugate of a polymer, an Anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions

a technology of angiogenesis agent and polymer, which is applied in the field of conjugation of polymer and anti-angiogenesis agent, can solve the problems of restricting their use, and achieve the effect of low polydispersity and high load of alendrona

Inactive Publication Date: 2014-07-31
RAMOT AT TEL AVIV UNIV LTD +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent teaches a new way to make certain compounds by combining a molecule called alendronate with a polymer. This process can be controlled and performed at a specific temperature. The result is a high amount of alendronate in the polymer and a uniform size distribution of the polymer. This can be useful in a variety of applications.

Problems solved by technology

Currently known agents used for treating bone related cancer and other angiogenesis-related conditions, at doses where anti-tumor activity is achieved, are characterized by high toxicity, which limits their use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Conjugate of a polymer, an Anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions
  • Conjugate of a polymer, an Anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions
  • Conjugate of a polymer, an Anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of HPMA Copolymer-ALN-TNP-470 Conjugate

[0494]The general synthesis of a HPMA-ALN-TNP-470 conjugate according to some embodiments of the present invention is depicted in FIG. 1.

[0495]HPMA-Gly-Gly-Pro-Nle-ALN-TNP-470 (SEQ ID NO: 12) conjugate was prepared in a two-step synthesis. First, an intermediate was synthesized by copolymerization of HPMA, ALN-methacrylamide monomer (MA-Gly-Gly-Pro-Nle-ALN; (SEQ ID NO: 8), and amino group-containing methacrylamide monomer (MA-Gly-Gly-Pro-Nle-ethylenediamine; SEQ ID NO: 13). Optionally, for the evaluation of intracellular trafficking, a polymerizable derivative of fluorescein isothiocyanate (FITC), N-methacryloylaminopropyl fluorescein thiourea (MA-FITC), was added to the monomer mixture. Next, TNP-470 was linked to free amino groups by nucleophilic substitution of the terminal chlorine of TNP-470.

[0496]Synthesis of ALN-containing monomer (MA-Gly-Gly-Pro-Nle-ALN ; SEQ ID NO: 8): MA-Gly-Gly-Pro-Nle (SEQ ID NO: 7) was synthesized by soli...

example 2

Effect of Combination Treatment of ALN and TNP-470 on Proliferation of Endothelial Cells In Vitro

[0515]Prior to conjugation of ALN and TNP-470 to HPMA copolymer backbone, the nature of the inhibitory effect of ALN and TNP-470 as a combined therapy on endothelial cells proliferation in vitro was evaluated. HUVEC were challenged with free or combined ALN and TNP-470. The results, presented in FIG. 2A show that combination treatments of ALN and TNP-470 decreased the IC's of the drugs as single treatments. ALN inhibited cell proliferation at inhibitory concentration IC30, 50, 70 of 10, 50, 90 μM, respectively, and TNP-470 inhibited cell proliferation at IC30, 50, 70 of 0.00025, 0.1, 1000 nM, respectively. Combination treatments I (serial concentrations of ALN and TNP-470 0.01 pM) and II (serial concentrations of TNP-470 and ALN 10 μM) inhibited HUVEC proliferation at IC30, 50, 70 of 0.2, 10, 30 μM and 0.00001, 0.004, 40 nM, respectively.

[0516]Combination index (CI)-isobologram equation ...

example 3

Binding of a HPMA -ALN-TNP-470 Conjugate to Bone Mineral Hydroxyapatite

[0517]One of the main characteristics of ALN besides its anti-angiogenic and antitumor activities is its pharmacokinetic profile which exhibits a strong affinity to bone mineral under physiological conditions. To determine if the activity of ALN is retained following polymer-conjugation, the affinity of the conjugate to bone mineral was evaluated by in vitro hydroxyapitate binding assay and FPLC analysis using Hitrap desalting column. As shown in FIG. 3B, unbound conjugates eluted as a single peak with a retention time of 1.9 minutes. AUC decreased in correlation with hydroxyapitate incubation time. Following 2 minutes of incubation with hydroxyapitate, 50% of the HPMA copolymer ALN-TNP-470 conjugate in the solution was bound to hydroxyapitate (see, FIG. 3C). This rapid binding rate to hydroxyapitate decreased after 10 minutes and finally reached a plateau after 175 minutes of incubation time with 92% of the HPMA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed.Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and an oligoaspartate bone targeting agent, and processes of preparing same, are further disclosed.Pharmaceutical compositions containing these conjugates and uses thereof in the treatment and monitoring of bone related disorders are also disclosed.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 12 / 993,855 filed on Nov. 22, 2010, which is a National Phase of PCT Patent Application No. PCT / IL2009 / 000511 having international filing date of May 21, 2009, which claims the benefit of priority of U.S. Provisional Patent Application Nos. 61 / 193,136 filed on Oct. 30, 2008 and 61 / 071,888 filed on May 22, 2008. The contents of the above applications are all incorporated by reference as if fully set forth herein in their entirety.STATEMENT OF GOVERNMENT INTEREST[0002]This invention was made with Government support under GM069847 awarded by National Institutes of Health. The Government has certain rights to this invention.SEQUENCE LISTING STATEMENT[0003]The ASCII file, entitled 58420SequenceListing.txt, created on Feb. 19, 2014, comprising 6,460 bytes, submitted concurrently with the filing of this application is incorporated herein by reference.FIELD AND BACKGROUND OF THE INVENTION[0004]Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/48A61K49/00
CPCA61K47/48176A61K47/48338A61K49/00A61K47/48038A61K47/48084A61K31/787A61K49/0043A61K49/0054A61K47/58A61P19/08A61P35/00A61P35/04
Inventor SATCHI-FAINARO, RONITSEGAL, EHUDKOPECEK, JINDRICHKOPECKOVA, PAVLAPAN, HUAIZHONG
Owner RAMOT AT TEL AVIV UNIV LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap